Premium
The in vitro effect of vitamin D3 analogue EB‐1089 on a human prostate cancer cell line (PC‐3)
Author(s) -
WANG X.,
CHEN X.,
AKHTER J.,
MORRIS D.L.
Publication year - 1997
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1997.00261.x
Subject(s) - trichloroacetic acid , thymidine , cell growth , vitamin , in vivo , cell culture , in vitro , endocrinology , growth inhibition , prostate , prostate cancer , vitamin d and neurology , medicine , cell , cancer , chemistry , biology , biochemistry , genetics , microbiology and biotechnology
Objective To determine the effect of vitamin D3 analogue (EB‐1089) on the growth and proliferation of a prostate cancer cell line (PC‐3). Materials and methods PC‐3 cells (10 4 cells per well) were plated into 24‐well tissue culture plates. After 24 h, the culture medium was replaced with one containing the vitamin D 3 analogue EB‐1089; a control treatment using only replacement medium was conducted in parallel. Cell proliferation was measured by the incorporation of 3 H‐thymidine 7 and 12 days after the addition of the vitamin D 3 analogue. Cells were precipitated with 5% trichloroacetic acid and the radioactivity determined using a scintillation counter. Each experiment was performed at least five times. Results There was a significant dose‐dependent inhibition of cell growth after 7 and 12 days of treatment with EB‐1089, varying from 40 to 70% of the 3 H‐thymidine incorporation by controls, respectively. The maximum inhibition occurred with 0.1 μmol/L EB‐1089 on day 7 and day 12 (both P <0.01). Longer incubation times appeared to have a greater effect when higher concentrations of EB‐1089 were used. Conclusion These in vitro studies have shown that the vitamin D 3 analogue EB‐1089 can significantly reduce the growth rate of the prostate cancer cell line PC‐3. This would support the hypothesis that deficiency of vitamin D increases the risk of prostate cancer and further in vivo testing of vitamin D is warranted for its potential role in active therapy.